Latest News “Nature Biotechnology: COVID-19 long haulers” Click here. “Ampio gets promising data on drug that could be used to treat COVID” Click here. Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in IndiaDate: September 21, 2021 | READ MORE > Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)Date: September 15, 2021 | READ MORE > Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of ActionDate: August 13, 2021 | READ MORE > Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual MeetingDate: August 12, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor ConferencesDate: August 11, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateDate: August 4, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual MeetingDate: July 29, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)Date: July 28, 2021 | READ MORE > Ampio Pharmaceuticals to Present at Aspen Lung ConferenceDate: July 27, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business UpdateDate: July 14, 2021 | READ MORE > Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory DistressDate: June 25, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® IndexDate: June 18, 2021 | READ MORE > Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAKDate: June 17, 2021 | READ MORE > Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to IndiaDate: June 15, 2021 | READ MORE > Ampio Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Summer Healthcare SymposiumDate: June 14, 2021 | READ MORE > Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and ExpoDate: June 14, 2021 | READ MORE > Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International CongressDate: May 21, 2021 | READ MORE > Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)Date: May 10, 2021 | READ MORE > Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business UpdateDate: May 5, 2021 | READ MORE > Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%Date: April 27, 2021 | READ MORE >
